- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Artenimol is approved by the EMA for use in the treatment of malaria, only as part of an artemisinin-based combination therapy (ACT) with piperaquine (trade name Eurartesim®). The FDA granted Orphan Drug designation for Eurartesim® in 2007 for the treatment of uncomplicated malaria (link to FDA Orphan Drug Designation record here).
The link to extended ADME data provided below is for the combined formulation with piperaquine.
For extended ADME data see the following:
European Medicines Agency (EMA)